Eski ve Yeni Kuşak Antiepileptik İlaçlar

Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551-563.

Sánchez JD, et al. Twenty-first century antiepileptic drugs: mechanisms, efficacy and safety. (Review). 2024.

Ng YH, et al. Antiseizure Medications: Advancements, Challenges, and Future Directions. 2025.

De Bellis M, et al. Adverse effects of antiseizure medications: a review of the evidence. Front Pharmacol. 2025.

Walia KS, et al. Side effects of antiepileptics: a review. Curr Neuropharmacol. 2004;2(1):73-86.

Zeng K, et al. Adverse effects of carbamazepine, phenytoin, valproate, and phenobarbital. Seizure. 2010.

Li C, et al. Antiepileptic Drug Combinations for Epilepsy: Mechanisms and Clinical Evidence. Int J Mol Sci. 2025.

Surya N, et al. Current role of brivaracetam in the management of epilepsy in adults and children: A systematic review. 2024.

International League Against Epilepsy (ILAE). Antiseizure medication guidelines and resources. Accessed 2023-2025.

European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. Revision 3. 2025.

Terman SW, et al. Current state of the epilepsy drug and device pipeline. Epilepsia. 2024.

Recent clinical studies on newer antiseizure medications including lacosamide, perampanel, brivaracetam, cannabidiol and cenobamate (2020–2025).